

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**SHANGHAI JUNSHI BIOSCIENCES CO., LTD.\***

**上海君實生物醫藥科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1877)**

**ANNOUNCEMENT IN RELATION TO THE  
APPROVAL BY THE CSRC OF THE APPLICATION FOR  
THE ISSUANCE OF A SHARES**

References are made to the announcement and circular (the “**Circular**”) dated 7 March 2022, the poll results announcement dated 6 April 2022, and the announcements dated 14 June 2022 and 16 September 2022 of Shanghai Junshi Biosciences Co., Ltd.\* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) in relation to the Proposed Issuance. Unless otherwise defined, all capitalized terms used herein shall have the same meanings as defined in the Circular.

The Board hereby announces that the Company has recently received the Approval Regarding the Registration of Shares Issued by Shanghai Junshi Biosciences Co., Ltd. to Target Subscribers (Zheng Jian Xu Ke [2022] No. 2616)\* 《關於同意上海君實生物醫藥科技股份有限公司向特定對象發行股票註冊的批覆》(證監許可[2022] 2616號) (the “**CSRC Approval**”) issued by the CSRC. Details of the CSRC Approval are as follows:

1. The application for registration of A Shares issued by the Company to target subscribers has been approved.
2. The issuance of A Shares by the Company shall be carried out in strict accordance with the application documents and issuance plan submitted to the Shanghai Stock Exchange.
3. The CSRC Approval shall be valid for a period of 12 months from the date of approval for registration.
4. From the date of approval for registration to the completion of the issuance, if any significant matters occur to the Company, the Company shall report such matter to the Shanghai Stock Exchange in a timely manner and handle such matter in accordance with relevant regulations.

The Board will deal with matters relating to the issuance of A Shares to target subscribers in accordance with the CSRC Approval and relevant laws and regulations, as well as the authorization granted at the EGM of the Company, within the specified time limit, and fulfill the information disclosure obligations of the Company in a timely manner. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Shanghai Junshi Biosciences Co., Ltd.\***  
**Mr. Xiong Jun**  
*Chairman*

Shanghai, the PRC, 3 November 2022

*As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong and Dr. Zou Jianjun as executive Directors; Dr. Wu Hai, Mr. Tang Yi and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun and Dr. Feng Xiaoyuan as independent non-executive Directors.*

\* *For identification purpose only*